Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs RGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: XNCR 4 – 2 RGNX Matrix Metrics: XNCR 8 – 2 RGNX

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -120.4% operating margin) and revenue trajectory (+454.9% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs RGNX
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.82β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63

6-Pillar Scorecard Institutional Category Breakdown (XNCR 4 – 2 RGNX)

Columns: Metric · XNCR · RGNX
1. Valuation Multiples XNCR
Forward P/E 68.0x N/M
Trailing P/E 68.0x N/M
PEG Ratio N/M 0.26x
EV / Revenue 14.8x 3.1x
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% -69.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $200M $154M
Market Cap $2.9B $500.9M
3. Profitability & Quality XNCR
Gross Margin -42.5% -64.5%
Operating Margin -72.7% -120.4%
Net Profit Margin -58.8% -113.9%
Return on Equity (ROE) -19.9% -113.2%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$176M -$155M
Cash Flow Margin -88.0% -100.6%
Net Cash / Leverage $101M Net Debt (0.29x D/E) $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 79.0% (10th %ile) 349.6% (52nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 30.2% of Rev ($61M) 55.9% of Rev ($86M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (8) vs RGNX (2)
Institutional Metric XNCR RGNX Criterion Row Edge
Market Capitalization
Scale
$2.9B $500.9M Larger Scale XNCR
Trailing P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Forward P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+454.9% -69.2% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% -120.4% Higher Margin XNCR
Net Profit Margin
Profitability
-58.8% -113.9% Higher Margin XNCR
Return on Equity (ROE)
Capital Efficiency
-19.9% -113.2% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 19% ($5–$16) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 1.82β · 76% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 45.3 / 100 (HOLD) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$200M $154M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% -64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev 0.26x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$155M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +48.26 pp
XNCR: +55.84% · RGNX: +7.58%
3M Horizon XNCR +72.84 pp
XNCR: +40.14% · RGNX: -32.7%
6M Horizon XNCR +190.11 pp
XNCR: +221.97% · RGNX: +31.86%
1Y Horizon XNCR +190.54 pp
XNCR: +154.54% · RGNX: -36.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period XNCR Revenue RGNX Revenue XNCR Op. Margin RGNX Op. Margin Margin Leader
FY2018 $40M $220M -195.5% 40.3% RGNX
FY2019 $160M $40M 8.8% -422.9% XNCR
FY2020 $120M $150M -62.6% -77.1% XNCR
FY2021 $280M $470M 15.9% 34.0% RGNX
FY2022 $160M $110M -50.1% -233.2% XNCR
FY2023 $170M $90M -75.8% -297.1% XNCR
FY2024 $110M $80M -161.5% -280.0% XNCR
FY2025 $130M $170M -141.4% -94.6% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs RGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -120.4% operating margin) and revenue trajectory (+454.9% vs. -69.2% YoY). Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.

XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus RGNX (-113.2% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.